Insulet (PODD) Aktsia Kursus

Insulet Kursus

NASDAQ·SULETUD
141,17USD+1,87 (+1,33 %)
Turg suletud

Revenue has compounded at 41,6% per year over the past 19 years to 2,71 B USD. Earnings per share have grown at 81,5% per year over the last 7 years. Insulet's net margin stands at 9,1%, up from 1,5% several years earlier. Analysts set a median price target of 367,20 USD, implying 160,1% above the current price. Of 34 analysts, 30 rate the stock a buy — an overall Buy consensus. The stock trades about 7% above its 52-week low.

Insulet aktsiahinnad

Maht
Detailid

Kurs

ⓘ

Ülevaade

Aktsiahinna diagramm pakub detailseid ja dĂŒnaamilisi ĂŒlevaateid Insulet-aktsia sooritusest, kuvades igapĂ€evaselt, nĂ€dalaselt vĂ”i kuuselt kokkuvĂ”etud kursid. Kasutajad saavad erinevate ajarahmade vahel liikudes aktsia ajalugu pĂ”hjalikult analĂŒĂŒsida ja teha teadlikke investeerimisotsuseid.

Intraday-funktsioon

Intraday-funktsioon pakub reaalajas andmeid ja vÔimaldab investoritel jÀlgida Insulet-aktsia kursikÔikumisi kauplemispÀeva jooksul, et teha Ôigeaegseid ja strateegilisi investeerimisotsuseid.

Kogutulu ja suhteline hinnamuutus

Vaadake Insulet-aktsia kogutulu, et hinnata selle kasumlikkust ajas. Suhtelise hinnamuutuse, mis pĂ”hineb valitud ajarahma esimesel saadaoleval kursil, annab ĂŒlevaate aktsia toimivusest ja aitab hinnata selle investeerimispotentsiaali.

Interpretatsioon ja investeering

Kasutage aktsiahinna diagrammis esitatud pĂ”hjalikke andmeid, et analĂŒĂŒsida Insulet turutrende, hinnaliikumisi ja potentsiaalseid tulusid. Tehke teadlikke investeerimisotsuseid, vĂ”rreldes erinevaid ajarahmasid ja hinnates Intraday andmeid optimeeritud portfelli haldamiseks.

Insulet Aktsia kursi ajalugu
KuupÀevInsulet Hind
7.8.2026141,17 USD
6.8.2026139,30 USD
5.8.2026132,05 USD
4.8.2026167,13 USD
3.8.2026169,70 USD
31.7.2026165,35 USD
30.7.2026165,68 USD
29.7.2026169,37 USD
27.7.2026168,13 USD
23.7.2026158,38 USD
22.7.2026158,93 USD
21.7.2026163,72 USD
20.7.2026167,37 USD
17.7.2026164,06 USD
16.7.2026164,43 USD
15.7.2026159,28 USD
14.7.2026159,12 USD
13.7.2026163,97 USD
10.7.2026161,28 USD
9.7.2026158,29 USD
8.7.2026157,93 USD
7.7.2026161,55 USD
6.7.2026157,51 USD
2.7.2026164,48 USD
1.7.2026159,79 USD
30.6.2026152,25 USD
29.6.2026157,24 USD
26.6.2026158,25 USD
25.6.2026153,82 USD
24.6.2026148,88 USD
23.6.2026143,90 USD
22.6.2026141,00 USD
18.6.2026145,42 USD
17.6.2026147,38 USD
16.6.2026146,82 USD
15.6.2026149,96 USD
12.6.2026148,80 USD
11.6.2026147,61 USD
10.6.2026155,75 USD
9.6.2026159,61 USD
8.6.2026151,51 USD
5.6.2026154,04 USD
4.6.2026148,94 USD
3.6.2026141,59 USD
2.6.2026144,07 USD
1.6.2026145,26 USD
29.5.2026142,90 USD
28.5.2026145,37 USD
27.5.2026145,00 USD
26.5.2026155,89 USD
22.5.2026152,80 USD
21.5.2026155,41 USD
20.5.2026154,51 USD
19.5.2026154,61 USD
18.5.2026152,49 USD
15.5.2026147,46 USD
14.5.2026148,68 USD
13.5.2026148,84 USD
12.5.2026158,35 USD
11.5.2026154,17 USD
8.5.2026154,16 USD
7.5.2026160,40 USD
6.5.2026151,28 USD
5.5.2026167,53 USD
4.5.2026171,39 USD
1.5.2026175,04 USD
30.4.2026172,14 USD
29.4.2026160,02 USD
28.4.2026182,87 USD
27.4.2026188,31 USD
24.4.2026189,56 USD
23.4.2026192,21 USD
22.4.2026193,62 USD
21.4.2026192,33 USD
20.4.2026200,87 USD
17.4.2026203,73 USD
16.4.2026201,47 USD
15.4.2026202,50 USD
14.4.2026201,49 USD
13.4.2026197,81 USD
10.4.2026196,93 USD
9.4.2026199,42 USD
8.4.2026203,51 USD
7.4.2026202,46 USD
6.4.2026203,50 USD
2.4.2026204,31 USD
1.4.2026207,04 USD
31.3.2026209,84 USD
30.3.2026208,01 USD
27.3.2026208,22 USD
26.3.2026218,11 USD
25.3.2026216,00 USD
24.3.2026225,50 USD
23.3.2026227,08 USD
20.3.2026227,10 USD
19.3.2026228,63 USD
18.3.2026230,28 USD
17.3.2026230,49 USD
16.3.2026224,66 USD
13.3.2026219,84 USD
12.3.2026236,07 USD
11.3.2026238,82 USD
10.3.2026238,24 USD
9.3.2026240,38 USD
6.3.2026237,01 USD
5.3.2026240,94 USD
4.3.2026242,89 USD
3.3.2026241,84 USD
2.3.2026245,45 USD
27.2.2026246,61 USD
26.2.2026251,50 USD
25.2.2026248,12 USD
24.2.2026245,25 USD
23.2.2026249,38 USD
20.2.2026241,89 USD
19.2.2026249,10 USD
18.2.2026258,07 USD
17.2.2026246,34 USD
13.2.2026242,74 USD
12.2.2026240,82 USD
11.2.2026250,85 USD
10.2.2026252,41 USD
9.2.2026245,57 USD
6.2.2026241,93 USD
5.2.2026243,15 USD
4.2.2026251,24 USD
3.2.2026251,22 USD
2.2.2026256,62 USD
30.1.2026255,81 USD
29.1.2026255,10 USD
28.1.2026258,20 USD
27.1.2026264,91 USD
26.1.2026271,31 USD
23.1.2026271,60 USD
22.1.2026280,00 USD
21.1.2026284,96 USD
20.1.2026284,25 USD
16.1.2026287,70 USD
15.1.2026286,49 USD
14.1.2026282,89 USD
13.1.2026278,17 USD
12.1.2026278,55 USD
9.1.2026289,04 USD
8.1.2026292,89 USD
7.1.2026299,17 USD
6.1.2026294,35 USD
5.1.2026283,51 USD
2.1.2026282,92 USD
31.12.2025284,24 USD
30.12.2025287,03 USD
29.12.2025287,36 USD
26.12.2025288,63 USD
24.12.2025288,82 USD
23.12.2025285,50 USD
22.12.2025291,57 USD
19.12.2025289,62 USD
18.12.2025292,88 USD
17.12.2025289,57 USD
16.12.2025288,73 USD
15.12.2025291,51 USD
12.12.2025295,70 USD
11.12.2025294,17 USD
10.12.2025295,19 USD
9.12.2025294,20 USD
8.12.2025296,19 USD
5.12.2025304,49 USD
4.12.2025315,92 USD
3.12.2025307,56 USD
2.12.2025309,00 USD
1.12.2025310,83 USD
28.11.2025327,19 USD
26.11.2025326,80 USD
25.11.2025328,85 USD
24.11.2025337,53 USD
21.11.2025331,17 USD
20.11.2025312,89 USD
19.11.2025346,36 USD
18.11.2025333,47 USD
17.11.2025328,02 USD
14.11.2025332,70 USD
13.11.2025332,67 USD
12.11.2025336,84 USD
11.11.2025326,28 USD
10.11.2025320,35 USD
7.11.2025319,82 USD
6.11.2025323,40 USD
5.11.2025314,44 USD
4.11.2025320,27 USD
3.11.2025318,77 USD
31.10.2025313,01 USD
30.10.2025311,95 USD
29.10.2025316,17 USD
28.10.2025324,34 USD
27.10.2025325,80 USD
24.10.2025320,91 USD
23.10.2025323,46 USD
22.10.2025329,22 USD
21.10.2025328,97 USD
20.10.2025326,85 USD
17.10.2025318,59 USD
16.10.2025316,29 USD
15.10.2025312,45 USD
14.10.2025318,30 USD
13.10.2025314,56 USD
10.10.2025314,52 USD
9.10.2025320,38 USD
8.10.2025315,49 USD
7.10.2025313,45 USD
6.10.2025311,69 USD
3.10.2025309,12 USD
2.10.2025312,21 USD
1.10.2025305,98 USD
30.9.2025308,73 USD
29.9.2025310,62 USD
26.9.2025318,00 USD
25.9.2025323,58 USD
24.9.2025326,97 USD
23.9.2025327,80 USD
22.9.2025335,12 USD
19.9.2025330,84 USD
18.9.2025333,51 USD
17.9.2025322,22 USD
16.9.2025332,13 USD
15.9.2025340,29 USD
12.9.2025341,78 USD
11.9.2025337,94 USD
10.9.2025337,61 USD
9.9.2025352,82 USD
8.9.2025349,56 USD
5.9.2025348,43 USD
4.9.2025346,47 USD
3.9.2025343,53 USD
2.9.2025344,92 USD
29.8.2025339,88 USD
28.8.2025337,60 USD
27.8.2025334,35 USD
26.8.2025331,83 USD
25.8.2025329,00 USD
22.8.2025330,77 USD
21.8.2025327,85 USD
20.8.2025333,00 USD
19.8.2025327,48 USD
18.8.2025323,07 USD
15.8.2025321,27 USD
14.8.2025315,78 USD
13.8.2025308,68 USD
12.8.2025309,63 USD
11.8.2025304,84 USD
Access this data via the Eulerpool API
Get Free API Key

Insulet tulu, EBIT, netkasum

  • 3 aastat

  • 5 aastat

  • 10 aastat

  • 25 aastat

  • Max

Tulu
EBIT
Netkasum
Details
Date
Tulu
EBIT
Netkasum
1. jaan 2023
1,70 B USD
220,00 M USD
206,30 M USD
1. jaan 2024
2,07 B USD
308,90 M USD
418,30 M USD
1. jaan 2025
2,71 B USD
473,80 M USD
247,10 M USD
1. jaan 2026 (e)
3,32 B USD
384,30 M USD
465,66 M USD
1. jaan 2027 (e)
3,94 B USD
454,96 M USD
579,00 M USD
1. jaan 2028 (e)
4,66 B USD
538,82 M USD
726,37 M USD
1. jaan 2029 (e)
5,44 B USD
628,33 M USD
877,48 M USD
1. jaan 2030 (e)
6,10 B USD
705,57 M USD
1,03 B USD

Insulet Kasumiaruanne, Bilanss, Rahavoogude aruanne

Viimati vÀrskendatud 10. aug 2026, 21:57
 
MÜÜGITULUB USD
KÄIBENÕUDLUS%
BRUTOMARGE%
BRUTOSISSETULEKB USD
EBITM USD
EBIT MARGINAAL%
PUHASTULUB USD
KASUMINÕUDLUS%
AKTSIADM
201520162017201820192020202120222023202420252026e2027e2028e2029e2030e
0,260,370,460,560,740,901,101,311,702,072,713,323,944,665,446,10
−8,6839,1626,5021,6031,0822,4921,4618,8530,0422,0430,7622,7518,3818,4516,6112,29
50,5757,6559,8365,7265,0464,3868,4961,6968,3069,7771,6071,6071,6071,6071,6071,60
0,130,210,280,370,480,580,750,811,161,451,942,382,823,343,894,37
−48,00−12,00−7,0027,0050,0054,0081,0036,00220,00308,00473,00384,00454,00538,00628,00705,00
−18,25−3,28−1,514,806,785,977,382,7612,9614,8717,4711,5511,5411,5411,5511,55
−0,07−0,03−0,03–0,010,010,02–0,210,420,250,470,580,730,881,03
43,14−61,64−7,14−111,54266,67−45,45166,67−75,005050,00102,91−40,9188,2624,3025,6120,8017,45
56,9357,4458,2461,0863,8965,9569,8170,0269,8674,0870,6770,6770,6770,6770,6770,67
Üksikasjad

Kasumiaruande pÔhinÀitajad

ⓘ

Tulu ja tulude kasv

Tulu on iga kasumiaruande lĂ€htepunkt — see mÔÔdab kogu mĂŒĂŒki, mille Insulet teenib oma pĂ”hitegevusest. Tulude kasv (vĂ€ljendatuna aasta-aasta protsentmuutusena) on ĂŒks olulisemaid Ă€ri hoogu nĂ€itajaid. JĂ€tkusuutliku kasvu ĂŒle 10% aastas peetakse tavaliselt tugevaks, samas kui kahanev tulu on tĂ”sine hoiatusmĂ€rk, mis nĂ”uab uurimist.

Brutomarginaal

Brutomarginaal = (Tulu − MĂŒĂŒdud kaupade kulu) Ă· Tulu. See nĂ€itab, kui suur protsent igast tuluallikast Insulet sĂ€ilitab pĂ€rast otseseid tootmiskulusid. KĂ”rged brutomarginaalid (ĂŒle 50%) on tĂŒĂŒpilised varade kergetele ettevĂ”tetele nagu tarkvara ja kaubamĂ€rgid, samas kui kapitaliintensiivsed tööstused nagu tootmine töötavad sageli alla 30%. VĂ”rrelge Insulet brutomarginaalide tööstushaarad ja jĂ€lgige neid aja jooksul, et tuvastada paremnevat vĂ”i halvenevat hinnakirja vĂ”imsust.

EBIT ja EBIT-marginaal

EBIT mÔÔdab Ă€rikasum — mis jÀÀb alles pĂ€rast kĂ”igi Ă€rikulude (sealhulgas uurimis- ja arenduskulud, mĂŒĂŒgikulud ja halduskulud) lahutamist brutokasum. EBIT-marginaal nĂ€itab seda tulude protsendina. Kuna see vĂ€listab intressid ja maksud, vĂ”imaldab EBIT Ă”iglast vĂ”rdlust erinevate vĂ”lastruktuuride ja maksujurisdiktsioonidega ettevĂ”tete vahel. Kasvav EBIT-marginaal nĂ€itab paranevat operatiivset tĂ”husust.

Puhaskasum ja kasum aktsia kohta (EPS)

Puhaskasum on ettevĂ”tte lĂ”plik kasum pĂ€rast kĂ”iki kulusid, intresse ja makse. Puhaskasumi jagamine vĂ€ljaantud aktsiate arvuga annab teile EPS — kĂ”ige mĂ”jukaim aktsia hindamise nĂ€itaja. JĂ€rjepidev EPS kasv on pikaajalise aktsiahinna kalliduse peamine juhtnöörid. Kontrollige alati, kas EPS kasv pĂ€rineb tegeliku kasumi parandamisest vĂ”i aktsiate tagasiostust, mis vĂ€hendab aktsiate arvu.

VĂ€ljastatud aktsiad

Koguarv aktsiate Insulet on vÀljastanud. Kahanev aktsiate arv (tagasiostude kaudu) suurendab EPS-i ja signaliseerib juhtimise enesekindlust. Kasvav aktsiate arv (aktsiate emissiooni kaudu) lahjendab olemasolevate aktsionÀride osa. JÀlgige alati seda numbrit koos EPS-ga, et saada tÀielik pilt aktsia kohta juhitud vÀÀrtusest.

AnalĂŒĂŒtikute hinnangud

Prognoositud arvud esindavad professionaalse analĂŒĂŒtikute konsensuselamisi. VĂ”rrelge neid prognoose Insulet ajalooliste kasvumÀÀrade vastu, et hinnata, kas ootused on realistlikud. EttevĂ”te, kes korrapĂ€raselt ĂŒletab konsensuselameid, kipub nĂ€gema oma aktsiahind ajas taunitud, samas kui korduvad jÀÀmid kahjustavad investorite usaldust.

Insulet aktsia marginaalid

Insulet marginaalanalĂŒĂŒs nĂ€itab brutomajanduste, EBIT-marginaali ja Insulet kasumi marginaali. EBIT marginaal (EBIT/mĂŒĂŒk) nĂ€itab mĂŒĂŒgi protsenti, mis jÀÀb operatiivseks kasumiks. Kasumi marginaal nĂ€itab mĂŒĂŒgi protsenti, mis jÀÀb Insulet.

  • 3 aastat

  • 5 aastat

  • 10 aastat

  • 25 aastat

  • Max

Brutomarginaal
EBIT marginaal
Kasumi marginaal
Details
Date
Brutomarginaal
EBIT marginaal
Kasumi marginaal
1. jaan 2021
68,45 %
7,44 %
1,53 %
1. jaan 2022
61,72 %
2,80 %
0,35 %
1. jaan 2023
68,35 %
12,96 %
12,16 %
1. jaan 2024
69,79 %
14,91 %
20,19 %
1. jaan 2025
71,63 %
17,50 %
9,12 %
1. jaan 2026 (e)
71,63 %
11,56 %
14,01 %
1. jaan 2027 (e)
71,63 %
11,56 %
14,71 %
1. jaan 2028 (e)
71,63 %
11,56 %
15,58 %

Insulet aktsia tulu, EBIT, kasum aktsia kohta

Insulet mĂŒĂŒk aktsia kohta nĂ€itab seega, kui palju tulu Insulet on antud perioodil aktsia kohta tekitanud. Kasum enne intresse ja makse aktsia kohta nĂ€itab, kuidas palju operatiivse kasumi vastab igale aktsiale. Kasum aktsia kohta nĂ€itab, kui palju kasumist vastab igale aktsiale.

  • 3 aastat

  • 5 aastat

  • 10 aastat

  • 25 aastat

  • Max

Tulu aktsia kohta
EBIT aktsia kohta
Kasum aktsia kohta
Details
Date
Tulu aktsia kohta
EBIT aktsia kohta
Kasum aktsia kohta
1. jaan 2021
15,74 USD
1,17 USD
0,24 USD
1. jaan 2022
18,64 USD
0,52 USD
0,07 USD
1. jaan 2023
24,29 USD
3,15 USD
2,95 USD
1. jaan 2024
27,96 USD
4,17 USD
5,65 USD
1. jaan 2025
38,32 USD
6,70 USD
3,50 USD
1. jaan 2026 (e)
46,25 USD
5,44 USD
6,48 USD
1. jaan 2027 (e)
54,75 USD
6,44 USD
8,05 USD
1. jaan 2028 (e)
64,84 USD
7,62 USD
10,10 USD

Insulet Ă€rimudel ja aktsia analĂŒĂŒs

Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future.

Insulet Employees

  • 3 aastat

  • 5 aastat

  • 10 aastat

  • 25 aastat

  • Max

Insulet Employees
Details
Date
Insulet Employees
1. jaan 2018
- Employees
1. jaan 2019
- Employees
1. jaan 2020
- Employees
1. jaan 2021
- Employees
1. jaan 2022
- Employees
1. jaan 2023
- Employees
1. jaan 2024
- Employees
1. jaan 2025
- Employees

Insulet Segmendid

Insulet kÀive segmendi jÀrgi (1/2)

  • 3 aastat

  • 5 aastat

  • Max

Total Omnipod Products
U.S
Total Omnipod
U.S. Omnipod
International
International Omnipod
Drug Delivery
Details
Date
Total Omnipod Products
U.S
Total Omnipod
U.S. Omnipod
International
International Omnipod
Drug Delivery
1. jaan 2018
0,00 USD
0,00 USD
0,00 USD
0,00 USD
0,00 USD
0,00 USD
0,00 USD
1. jaan 2019
0,00 USD
0,00 USD
0,00 USD
0,00 USD
0,00 USD
0,00 USD
0,00 USD
1. jaan 2020
0,00 USD
0,00 USD
834,90 M USD
526,90 M USD
0,00 USD
308,00 M USD
69,50 M USD
1. jaan 2021
0,00 USD
0,00 USD
1,01 B USD
651,50 M USD
0,00 USD
359,90 M USD
87,40 M USD
1. jaan 2022
0,00 USD
0,00 USD
1,25 B USD
884,80 M USD
0,00 USD
363,00 M USD
57,50 M USD
1. jaan 2023
1,66 B USD
1,25 B USD
0,00 USD
0,00 USD
410,10 M USD
0,00 USD
36,00 M USD
1. jaan 2024
2,03 B USD
1,51 B USD
0,00 USD
0,00 USD
523,40 M USD
0,00 USD
38,90 M USD
1. jaan 2025
2,67 B USD
1,92 B USD
0,00 USD
0,00 USD
754,30 M USD
0,00 USD
34,10 M USD

Insulet kÀive segmendi jÀrgi (2/2)

  • 3 aastat

  • 5 aastat

  • Max

Total Omnipod
U.S. Omnipod
International Omnipod
Drug Delivery
Details
Date
Total Omnipod
U.S. Omnipod
International Omnipod
Drug Delivery
1. jaan 2018
0,00 USD
323,47 M USD
170,23 M USD
60,02 M USD
1. jaan 2019
673,50 M USD
0,00 USD
0,00 USD
64,70 M USD
1. jaan 2020
0,00 USD
0,00 USD
0,00 USD
0,00 USD
1. jaan 2021
0,00 USD
0,00 USD
0,00 USD
0,00 USD
1. jaan 2022
0,00 USD
0,00 USD
0,00 USD
0,00 USD
1. jaan 2023
0,00 USD
0,00 USD
0,00 USD
0,00 USD
1. jaan 2024
0,00 USD
0,00 USD
0,00 USD
0,00 USD
1. jaan 2025
0,00 USD
0,00 USD
0,00 USD
0,00 USD

Insulet kÀive regiooni jÀrgi

  • 3 aastat

  • 5 aastat

  • Max

United States
International
All other
Details
Date
United States
International
All other
1. jaan 2018
391,80 M USD
0,00 USD
172,02 M USD
1. jaan 2019
485,10 M USD
0,00 USD
253,10 M USD
1. jaan 2020
596,40 M USD
308,00 M USD
0,00 USD
1. jaan 2021
738,90 M USD
359,90 M USD
0,00 USD
1. jaan 2022
942,30 M USD
363,00 M USD
0,00 USD
1. jaan 2023
1,29 B USD
410,10 M USD
0,00 USD
1. jaan 2024
1,55 B USD
523,40 M USD
0,00 USD
1. jaan 2025
1,95 B USD
754,30 M USD
0,00 USD

Insulet hindamine Ôiglase vÀÀrtuse alusel

Üksikasjad

Õiglase vÀÀrtuse hinnang

ⓘ

Mis on Ôiglane vÀÀrtus?

Õiglane vÀÀrtus on hinnang selle kohta, millega aktsia on tegelikult "vÀÀrt" selle finantsalusel, sĂ”ltumata praegusest turuhinnast. Kui arvutatud Ă”iglane vÀÀrtus ĂŒletab praegust aktsia hinda, vĂ”ib aktsia olla alahinnatud — ja vastupidi. See diagramm nĂ€itab kolme erinevat Ă”iglase vÀÀrtuse lĂ€henemist, et saaksite neid omavahel kontrollida.

Tulul pÔhinev Ôiglane vÀÀrtus

Arvutatakse korrutades praeguse kasum aktsia kohta (EPS) valitud mitmeaastase perioodi keskmise ajaloolise P/E suhtega. Mitme aasta jooksul silumamine filtreerib vĂ€lja ajutised tĂ”usud vĂ”i langused. Kui see Ă”iglane vÀÀrtus ĂŒletab turuhinda, viitab see sellele, et aktsia on odav vĂ”rreldes selle kasumitegemise vĂ”imega.

NĂ€ide: Õiglane vÀÀrtus (kasum) 2022 = EPS 2022 × Keskmine P/E 2019–2021

Tulul pÔhinev Ôiglane vÀÀrtus

Tuletatud tulupooluse korrutamisel keskmise ajaloolise hinna ja mĂŒĂŒgi suhtega. See meetod on eriti kasulik ettevĂ”tete puhul, millel on volatiilne vĂ”i ajutiselt langev kasum, kuna mĂŒĂŒk kipub olema stabiilsem kui kasumid. See vastab kĂŒsimusele: "Millise hinnaga on turg ajalooliselt hinnanud selle ettevĂ”tte mĂŒĂŒgi dollarit?"

NĂ€ide: Õiglane vÀÀrtus (kasum) 2022 = MĂŒĂŒk aktsia kohta 2022 × Keskmine P/S 2019–2021

Dividendil pÔhinev Ôiglane vÀÀrtus

Arvutatakse jagades dividendi aktsia kohta keskmise ajaloolise dividendi tootlusega. See lĂ€henemisviis on kĂ”ige asjakohane kĂŒpsete, jĂ€rjepidevalt dividende maksvate ettevĂ”tete jaoks. Kui saadud Ă”iglane vÀÀrtus on praegusest hinnast kĂ”rgem, tĂ€hendab see, et aktsia pakub paremat tootlust kui selle ajaloo keskmine.

NĂ€ide: Õiglane vÀÀrtus (dividend) 2022 = Dividend aktsia kohta 2022 Ă· Keskmine tootlus 2019–2021

Kuidas seda diagrammi kasutada

Kui kĂ”ik kolm Ă”iglase vÀÀrtuse joont koonduvad praeguse hinna kohal, tugevdab see veenvust, et aktsia on alahinnatud. Kui nad hajuvad, uurige, miks — see vĂ”ib nĂ€idata struktuurimuutust marginaalidel, vĂ€ljamakse poliitikale vĂ”i kasvumÀÀrale. Paremalt poolel olevad edasiulatusvad hinnangud laiendavad analĂŒĂŒsi, kasutades prognoositavaid pĂ”hifaktoreid, aidates teil hinnata, kas praegune hind juba kajastab tuleviku kasvuootusi.

Insulet hindamine ajalooline P/E-suhtarv, EBIT-multiple ja P/S-suhtarv

Insulet aktsia aastane tootlus

Üksikasjad

Aastane tootlus

ⓘ

Mida see diagramm nÀitab

See diagramm jagab aastase kogu tootluse kaheks komponendiks: hinna tootluseks (kasumid vÔi kahjumid aktsia hinna liikumisest) ja dividendi tootluseks (tulu, mis saadud dividendi maksest). Koos esindavad need kogu tootlust, mida investor oleks iga kalendriaasta jooksul teeninud.

Hinna tootlus

Hinna tootlus mÔÔdab protsendi muutust aktsia hinnas 1. jaanuaari ja 31. detsembri vahel igal aastal. Positiivsed tulpd nĂ€itavad, et aktsia tĂ”usis; negatiivsed tulbad nĂ€itavad langust. See on komponent, mille peale enamik investoreid keskendub, kuid see rÀÀgivad ainult osale lugu — eriti dividende maksavate aktsiate puhul.

Dividendi tootlus

Dividendi tootlus esindab aasta jooksul makstud dividendist saadud tulu, vĂ€ljendatuna alusaktsiate hinnaprotsendina. Kuigi see vĂ”ib nĂ€ida vĂ€ike igal aastal (tavaliselt 1–4% tuntud ettevĂ”tete jaoks), kumuleeruvad dividendid mĂ€rkimisvÀÀrselt kĂŒmnendite jooksul ja on ajalooliselt osutanud ligikaudu 40% kogu aktsiaturuil tootlusele.

Mida otsida

Uurige, kui palju aastaid nĂ€itas positiivseid ja negatiivseid tootlusi, et hinnata jĂ€rjepidevust. Aktsia, millel on enamasti positiivsed aastad ja vĂ€ikesed langused, viitab madalamale riskile. Samuti vĂ”rrelge aastast tootlust kohalike indeksitega — pidevalt turu ĂŒletamine on tugeva investeeringu tunnusjoon. Pööra tĂ€helepanu halvaimaele aastale: allapoole riski mĂ”istmine on sama tĂ€htis kui ĂŒlespoolse potentsiaali Ă€raaita.

Insulet vÀljaolevad aktsiad

Aktsiate arv ettevÔttes Insulet oli 2025. aastal 70,67 M. See nÀitab, mitmeks aktsiaks on Insulet jagatud. Kuna aktsionÀÀrid on ettevÔtte omanikud, esindab iga aktsia vÀike osa ettevÔtte omandiÔiguse.

  • 3 aastat

  • 5 aastat

  • 10 aastat

  • 25 aastat

  • Max

Aktsiate arv
Details
Date
Aktsiate arv
1. jaan 2021
69,81 M Aktsiad
1. jaan 2022
70,02 M Aktsiad
1. jaan 2023
69,86 M Aktsiad
1. jaan 2024
74,08 M Aktsiad
1. jaan 2025
70,67 M Aktsiad
1. jaan 2026 (e)
70,67 M Aktsiad
1. jaan 2027 (e)
70,67 M Aktsiad
1. jaan 2028 (e)
70,67 M Aktsiad

Aktuaalsed Insulet prognoosid ja kursieelistused August 2026

AnalĂŒĂŒtikute kurssizihtpunktid 2026
Δ Hinnasiht eelmise kuuga vĂ”rreldes
4,00 %
Osta
88,24 % (30)
Hoida
8,82 % (3)
MĂŒĂŒa
2,94 % (1)
12M Hinnasiht
367,20
Viimane hind
141,17
Valuuta
USD
12K Rendite-potentsiaal
160,11 %
LTM Tootlus
0 %

Insulet Analyst Rating Actions

DateFirmActionRatingReliability
13.7.2026
Truist Securities
Truist Securities
MaintainedBuy–
13.7.2026
RBC Capital
RBC Capital
MaintainedOutperform52
10.7.2026
Stifel
Stifel
MaintainedBuy–
8.7.2026
Citigroup
Citigroup
MaintainedNeutral48
6.7.2026
Evercore ISI Group
Evercore ISI Group
MaintainedOutperform62
12.6.2026
Truist Securities
Truist Securities
MaintainedBuy–
28.5.2026
Citigroup
Citigroup
MaintainedNeutral48
27.5.2026
RBC Capital
RBC Capital
MaintainedOutperform52
27.5.2026
BTIG
BTIG
MaintainedBuy–
18.5.2026
B of A Securities
B of A Securities
MaintainedBuy70

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Insulet Tulemuste teadaandmised

2025

Insulet Kasumiprognoosid ja kasumiĂŒllatused

KuupÀevEPS hinnangEPS tegelikTulu hinnangAktsia reaktsioonAruande kvartal
5.8.20261,47USD-802,84 MUSD-2026 Q2
6.5.20261,22USD-742,92 MUSD-2026 Q1
18.2.20261,48USD-784,07 MUSD-2025 Q4
7.11.20240,77USD-528,62 MUSD-2024 Q3
2.5.20240,45USD-451,34 MUSD-2024 Q1
21.2.20240,67USD-469,69 MUSD-2023 Q4
2.8.20230,23USD-355,72 MUSD-2023 Q2
3.5.20230,17USD-338,84 MUSD-2023 Q1
21.2.20230,23USD-335,82 MUSD-2022 Q4
3.11.20220,15USD-317,07 MUSD-2022 Q3
...

EESG©

Eulerpool ESG Scorecard© aktsialle Insulet

74/100
64
Environment
94
Social
64
Governance
E

Keskkond

20
Otsesed emissioonid1383
Ostetud energia pÔhjustatud kaudsed heitmed11 057
VÀÀrtusahela sees olevad kaudsed heitkogused—
CO₂-heited12 440
CO₂ vĂ€hendamise strateegia
Söeenergia
Tuumaenergia
Loomkatsed
Nahk & Karusnahk—
Pestitsiidid—
PalmiĂ”li—
Tubakas
Geneetiline tehnoloogia
Kliimakava—
JĂ€tkusuutlik metsamajandus—
RinglussevÔtu mÀÀrused
KeskkonnasÔbralikus pakkimine
Ohtlikud ained
KĂŒtusekulu ja tĂ”husus
Veekulutus ja tÔhusus
S

Ühiskond

20
Naiste töötajate osakaal46
Naiste osakaal juhtkonnast—
Aasia töötajate osakaal—
Aasia juhtimise osakaal—
Hispaania/Latino töötajate osakaal—
Hispaania/Latino juhtimise osakaal—
Mustade töötajate osakaal—
Must juhtimise osakaal—
Valget töötajate osakaal—
Valge juhtimise osakaal—
TĂ€iskasvanute sisu
Alkohol
Relvastus—
Relvad
HasartmÀng
SÔjalised lepingud
InimÔiguste kava
Andmekaitse kava—
Tööohutus ja tervishoid
Katoliku
G

Juhtimus

4
JĂ€tkusuutlikkuse aruanne
SidusrĂŒhmade kaasamine
Tagasikutsumise poliitika
Kartelliseadus

Eulerpool ESG Scorecard© on Eulerpool Research Systemsi rangelt autoriĂ”igustega kaitstud intellektuaalomand. Iga volitamata kasutamine, jĂ€ljendamine vĂ”i rikkumine nĂ”utakse aktiivselt ja vĂ”ib kaasa tuua mĂ€rkimisvÀÀrseid Ă”iguslikke tagajĂ€rgi. Litsentside, koostöö vĂ”i kasutamisĂ”iguste saamiseks palume vĂ”tta meiega otse ĂŒhendust meie kontaktvormi kaudu. Kontaktivorm .

Insulet aktsia aktsionÀride struktuur

% Nimi
12,05852%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
8,86952%
BLACKROCK, INC.
BLACKROCK, INC.
7,87693%
Fidelity Management & Research Company LLC
Fidelity Management & Research Company LLC
6,37019%
VANGUARD CAPITAL MANAGEMENT LLC
VANGUARD CAPITAL MANAGEMENT LLC
6,15645%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
6,13328%
Capital Research Global Investors
Capital Research Global Investors
...

Insulet Beneficial Ownership Filings (SEC 13D/G)

Free Float
99,6%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
11,48%
Abigail P. Johnson
Abigail P. Johnson
SEC ↗
11,00%
Identification #52-2069785 (formerly 13-2631108)
Identification #52-2069785 (formerly 13-2631108)
SEC ↗
10,70%
95-1411037
95-1411037
SEC ↗
9,98%
James E. Flynn
James E. Flynn
SEC ↗
9,34%
13-3017981
13-3017981
SEC ↗
8,21%
Wellington Management Group LLP
Wellington Management Group LLP
SEC ↗
8,10%
WILLIAM J. LINK
WILLIAM J. LINK
SEC ↗
8,10%
VERSANT VENTURES I, LLC
VERSANT VENTURES I, LLC
SEC ↗
8,10%
SAMUEL D. COLELLA
SAMUEL D. COLELLA
SEC ↗
8,10%
ROSS A. JAFFE
ROSS A. JAFFE
SEC ↗

Insulet Juhtkond ja nÔukogu

19 members · avg. age 55 · 42 % women

EB

Mr. Eric Benjamin (42)

Chief Operating Officer

4,14 M USD

Management

JK

Mr. John Kapples (65)

Senior Vice President, General Counsel

2,91 M USD
DM

Mr. Dan Manea (58)

Chief Human Resources Officer, Senior Vice President

1,74 M USD
LB

Ms. Lauren Budden (49)

Chief Accounting Officer, Group Vice President, Corporate Controller

1,63 M USD
FP

Ms. Flavia Pease (52)

Chief Financial Officer, Executive Vice President · alates 2024

602 925,00 USD
AM

Ms. Ashley Mcevoy (54)

President, Chief Executive Officer, Director · alates 2025

–
LC

Ms. Laetitia Cousin (49)

Senior Vice President - Regulatory Affairs, Quality Assurance and Compliance

–

Board of Directors

TS

Mr. Timothy Scannell (60)

Independent Chairman of the Board

414 354,00 USD
EW

Ms. Elizabeth Weatherman (65)

Independent Director

333 461,00 USD
WF

Dr. Wayne Frederick (53)

Independent Director

330 961,00 USD
MM

Mr. Michael Minogue (58)

Independent Director

325 961,00 USD
LB

Dr. Luciana Borio (54)

Independent Director

318 461,00 USD
JH

Dr. Jessica Hopfield (60)

Independent Director

313 461,00 USD

Insulet Supply Chain

Insulet Tarneahel

Korrelatsioon: kui tihedalt liiguvad aktsiahinnad koos

Sama suundPuudub seosVastupidine
4 companies
#NimiTrend
1
Abbott Laboratories
Tarnija·Klient·Health Care Equipment & Supplies·US
0,51
0,64
0,85
0,61
0,34
0,64
2
DexCom
Tarnija·Klient·Health Care Equipment & Supplies·US
−0,40
0,88
0,91
0,84
0,83
0,55
#NimiTrend
1
Amgen
Klient·Biotechnology·US
0,84
−0,65
0,13
−0,18
−0,49
−0,44
2
Olympic Circuit Tech
Tarnija·Electronic Equipment, Instruments & Components·CN
−0,14
−0,79
0,09
0,16
−0,30
−0,31

Korduma kippuvad kĂŒsimused Insulet aktsia kohta

The business model of Insulet Corp revolves around the development and commercialization of innovative medical devices for individuals with diabetes. Insulet is known for its flagship product, the Omnipod Insulin Management System, which is a tubeless insulin pump. This system is designed to provide continuous subcutaneous insulin delivery with customizable insulin plans and improved convenience for users. Insulet Corp focuses on helping diabetes patients manage their condition effectively and ensuring a better quality of life. With their unique and advanced technology, Insulet continues to make significant contributions to the diabetes healthcare industry.

Insulet Corp is primarily active in the healthcare industry, specifically in the medical devices sector.

The main competitors of Insulet Corp in the market are Medtronic plc, Tandem Diabetes Care, Inc., and Dexcom, Inc. These companies operate in the same industry sector and offer similar products and services. Medtronic plc is a multinational medical device company, Tandem Diabetes Care, Inc. specializes in insulin pumps, and Dexcom, Inc. provides continuous glucose monitoring systems. These competitors pose challenges to Insulet Corp in terms of market share and product innovation. Competing with these industry leaders, Insulet Corp strives to differentiate itself through its Omnipod System, a unique tubeless insulin delivery system.

Insulet Corp is a leading medical technology company headquartered in Massachusetts, United States. Founded in 2000, Insulet is focused on improving the lives of individuals with diabetes through the development and manufacturing of innovative insulin delivery systems. The company is renowned for its flagship product, the Omnipod Insulin Management System, which offers patients a unique tubeless and wireless insulin pump experience. Insulet has a rich history of achievement and continuous growth, earning recognition for its dedication to patient-centric solutions. With a strong commitment to advancing diabetes care, Insulet Corp has positioned itself as a trusted and reliable provider in the medical technology industry.

Insulet Corp has achieved several significant milestones in its history. One of the notable achievements is the development and introduction of the Omnipod System, a tubeless insulin delivery system that has revolutionized diabetes management. This innovative product has gained wide acceptance and has positively impacted the lives of many patients. Additionally, Insulet Corp has successfully expanded its global presence, securing regulatory approvals in various countries and establishing partnerships with healthcare providers worldwide. The company has also demonstrated consistent financial growth and market success, solidifying its position as a leader in the diabetes technology industry.

Insulet Corp primarily operates in the United States, Canada, Europe, and the Middle East.

Insulet Corp is a renowned company in the stock market known for its values and corporate philosophy. The company aims to improve the lives of people with diabetes through innovative and reliable technologies. Insulet Corp values patient-centricity by providing user-friendly and discreet products like the Omnipod System. Their corporate philosophy revolves around continuous innovation, teamwork, and a commitment to making a difference in diabetes management. Insulet Corp's vision is to empower individuals with diabetes to live life to the fullest, offering them better control, flexibility, and convenience. With a dedicated focus on diabetes care, Insulet Corp sets itself apart in the market, making it a highly regarded company among investors.

Analysts currently set an average price target of 363,98 USD for the Insulet stock (median: 367,20 USD), implying +157,8 % versus the latest price. The consensus is based on 34 analyst ratings.

Insulet AnalĂŒĂŒtikute kurssizihtpunktid 2026

34 analysts currently rate the Insulet stock: 31 recommend buying, 2 holding and 1 selling. For 2026, analysts expect Insulet to generate revenue of 3,32 B USD and earnings per share of 6,59 USD.

Insulet AnalĂŒĂŒtikute kurssizihtpunktid 2026

Converted at the current exchange rate, the Insulet share trades at 122,18 EUR (141,17 USD).

The Insulet share (PODD) is listed on 5 stock exchanges, including: NASDAQ (PODD), Frankfurt (GOV.F), MĂŒnchen (GOV.MU), DĂŒsseldorf (GOV.DU), SIX (ZĂŒrich) (GOV.SW).

Insulet Corporation is a company specializing in the development and manufacturing of personalized insulin delivery systems. The company is headquartered in Acton, Massachusetts, USA and was founded in 2000.

oodatav Insulet kÀive on 3,32 B USD. See nÀitaja pÔhineb praegusel finantsandmetel ja peegeldab ettevÔtte Àritulemuseid.

oodatav Insulet kasum on 465,66 M USD. Netokasum peegeldab ettevÔtte kasumlikkust pÀrast kÔigi kulude mahaarvamist.

VÔrdlusarvud hinna ja kasumiga (P/E) Insulet jaoks on praegu 21,42. P/E-suhtarv vÔrdleb praegust aktsiahinnad kasumiga aktsia kohta ja aitab investoritel hinnata Insulet aktsia vÀÀrtust.

Kursuse ja mĂŒĂŒgimahu suhe (P/S) Insulet jaoks on praegu 3,00. P/S-suhtarv vĂ”rdleb börsikapitalisatsooni aastase tuluga ja teenib hindamismÔÔdikuna Insulet aktsia jaoks.

Eulpooli kvaliteedinÀitaja Insulet jaoks on 6/10.

Insulet ISIN on US45784P1012. ISIN (rahvusvaheline vÀÀrtpaberi identifitseerimise number) on vÀÀrtpaberite globaalne unikaalne tuvastaja.

Insulet WKN on A0MQX8. WKN (Wertpapierkennnummer) on kuuekohaline saksa vÀÀrtpaberi identifitseerimise number.

Insulet ticker on PODD. Ticker-sĂŒmbol kasutatakse Insulet aktsiate kauplemiseks börsil.

Insulet maksis dividende igal aastal viimase 0 aasta jooksul.

Insulet kuulub sektorisse 'Tervishoid'.

Insulet dividendid jagatakse vÀlja valuutas USD.

KĂ”ik teised nĂ€itajad ja analĂŒĂŒsid Insulet kohta sĂŒgavamalt

Meie Insulet-aktsia analĂŒĂŒs sisaldab olulisi finantsnĂ€itajaid, nagu kĂ€ive, kasum, P/E suhe, P/S suhe, EBIT, samuti teavet dividendi kohta. Lisaks kĂ€sitleme aspekte nagu aktsiad, turukapitalisatsioon, vĂ”lad, omakapital ja kohustused ettevĂ”ttes Insulet. Kui otsite nende teemade kohta pĂ”hjalikumat teavet, pakume teile meie alamlehtedel ĂŒksikasjalikke analĂŒĂŒse:

Insulet Aktsia
Insulet Tulud→
Insulet Aktsia
Insulet Puhaskasum→
Insulet Aktsia
Insulet P/E→
Insulet Aktsia
Insulet P/S→
Insulet Aktsia
Insulet EBIT→
Insulet Aktsia
Insulet Dividend→
Insulet Aktsia
Insulet Direktorite Tehingud→
Insulet Aktsia
Insulet Aktsiad→
Insulet Aktsia
Insulet TuruvÀÀrtus→
Insulet Aktsia
Insulet VĂ”lg→
Insulet Aktsia
Insulet Kohustused→
Insulet Aktsia
Insulet Omakapital→
Insulet Aktsia
Insulet AAQS→
Insulet Aktsia
Insulet Töötajad→
Insulet Aktsia
Insulet ROE→
Insulet Aktsia
Insulet ROA→
Insulet Aktsia
Insulet ROCE→
Insulet Aktsia
Insulet News→
Insulet Aktsia
Insulet AnalĂŒĂŒtikute kurssizihtpunktid→

Tervishoid Aktsiad

Intai TechnologyInstituto de DiagnosticoIntco Medical Technology CoInspireMDIntech BiopharmInspire Medical SystemsInteger HoldingsInspire IVF PCLIntegra Lifesciences HoldingsInspiration Healthcare GroupIntegragenInspira Technologies Oxy BHNKĂ”ik aktsiaid A–Z →